Sunday, May 12, 2019

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.


from Reuters: Health News https://reut.rs/2HbDAZA

Related Posts:

  • LATEST HEALTH NEWSNovartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with stri… Read More
  • LATEST HEALTH NEWS(Reuters Health) - States that require adults on Medicaid to work a set number of hours to get benefits may find many people lose coverage because behavioral health conditions and other chronic health problems make it hard fo… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Patients who see their doctors in the morning are a lot more likely to be referred for screenings for breast and colon cancer than patients with end-of-the-day appointments, a new study suggests. from … Read More
  • LATEST HEALTH NEWS(Reuters Health) - Suicide is the only cause of death that is higher among doctors than the general population, according to two Canadian physicians who coauthored an information sheet about physician suicide. from Reute… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Younger boys who play lacrosse are more likely to get injured and sustain concussions than high school or college players, a U.S. study suggests. from Reuters: Health News https://reut.rs/2VzY7jq … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner